Literature DB >> 9158232

Subgroups of smokers with different success rates after use of transdermal nicotine.

G E Swan1, L M Jack, M M Ward.   

Abstract

To identify subgroups of smokers with different success rates, we applied "tree-structured survival analysis" (TSSA) to data from a previously published trial of transdermal nicotine. The subjects who received active treatment (14 mg patch, n = 275, or the 21 mg patch, n = 262) constituted the sample for this analysis. Using age, gender, the Fagerstrom Tolerance Questionnaire (FTQ), motivation to quit, number of cigarettes smoked at baseline, and body mass index (BMI) as classification variables, TSSA identified two subgroups within the 14 mg patch group and four subgroups of smokers within the 21 mg patch group. Among those receiving the 14 mg patch, individuals with a BMI greater than 26.4 kg/m2 relapsed sooner than did those with a BMI less than or equal to this value. Within the 21 mg patch group, the survival curve for males was significantly different from that observed in females, with males experiencing a longer time to relapse after treatment than did females. Among females, those with a higher motivation to quit relapsed more slowly than did those women with less motivation to quit. This information may be helpful to clinicians seeking to match specific patients to specific treatments with traditional nicotine in order to maximize treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158232

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  35 in total

1.  Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation.

Authors:  Gary E Swan; Karen Suchanek Hudmon; Lisa M Jack; Kymberli Hemberger; Dorit Carmelli; Taline V Khroyan; Huijun Z Ring; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Dale McBride; Neal Benowitz; Chris Webster; Kirk C Wilhelmsen; Heidi S Feiler; Barbara Koenig; Lorraine Caron; Judy Illes; Li S-C Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

2.  Predictors of long-term outcome of a smoking cessation programme in primary care.

Authors:  Gonzalo Grandes; Josep M Cortada; Arantza Arrazola; Jon P Laka
Journal:  Br J Gen Pract       Date:  2003-02       Impact factor: 5.386

3.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

4.  Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Authors:  Gary E Swan; Lisa M Jack; Harold S Javitz; Tim McAfee; Jennifer B McClure
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial.

Authors:  Benjamin A Toll; Stephanie S O'Malley; Nicole A Katulak; Ran Wu; Joel A Dubin; Amy Latimer; Boris Meandzija; Tony P George; Peter Jatlow; Judith L Cooney; Peter Salovey
Journal:  Psychol Addict Behav       Date:  2007-12

6.  Reduced nicotine reward in obesity: cross-comparison in human and mouse.

Authors:  Julie A Blendy; Andrew Strasser; Carrie L Walters; Kenneth A Perkins; Freda Patterson; Robert Berkowitz; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

7.  C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency.

Authors:  Leslie K Jacobsen; Kenneth R Pugh; W Einar Mencl; Joel Gelernter
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

8.  Impact of baseline weight on smoking cessation and weight gain in quitlines.

Authors:  Terry M Bush; Michele D Levine; Brooke Magnusson; Yu Cheng; Xiaotian Chen; Lisa Mahoney; Lyndsay Miles; Susan M Zbikowski
Journal:  Ann Behav Med       Date:  2014-04

Review 9.  Use of sustained-release bupropion in specific patient populations for smoking cessation.

Authors:  Serena Tonstad
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Clinical efficacy of bupropion in the management of smoking cessation.

Authors:  Douglas Jorenby
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.